- Citations, last 5 years
- 596
- Works, last 5 years
- 40
- h-index
- 48
- Scientists listed
- 13
- Grants since 2016
- 64
Grants received
2024–2027 · research · R44
Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii
Tsuyoshi Uehara · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii
Tsuyoshi Uehara · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
Glen Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections
Glen Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2027 · research · R44
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
Glen Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2022–2026 · research · R44
Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa
Bin Liu · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa
Bin Liu · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa
Bin Liu · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2026 · research · R01
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2026 · research · R01
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2026 · research · R01
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2026 · research · R01
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2027 · research · R01
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Discovery of inhibitors that target HBx for the treatment of chronic HBV infection
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2023 · contract · N01
Development of Therapeutic Products for Antibiotic Resistant Bacteria
Daniel Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Discovery of antiviral inhibitors of Ebola virus replication
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2021 · contract · N01
Development of Therapeutic Products for Antibiotic Resistant Bacteria
Daniel Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2023 · research · R43
Discovery of inhibitors that target HBx for the treatment of chronic HBV infection
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Discovery of antiviral inhibitors of Ebola virus replication
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2025 · contract · N01
Development of Therapeutic Products for Antibiotic Resistant Bacteria
Daniel Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2026 · contract · N01
Development of Therapeutic Products for Antibiotic Resistant Bacteria
Daniel Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2026 · contract · N01
Development of Therapeutic Products for Antibiotic Resistant Bacteria
Daniel Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2024 · research · R01
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae
Denis Marc Daigle · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2025 · research · R01
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae
Denis Marc Daigle · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2024 · research · R01
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae
Denis Marc Daigle · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2024 · research · R01
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae
Denis Marc Daigle · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2024 · research · R01
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae
Denis Marc Daigle · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2024 · research · R01
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2023 · research · R01
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2023 · research · R01
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2023 · research · R01
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2023 · research · R01
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library
Steven Armen Boyd · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Discovery of inhibitors of Zika virus
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Advancement to IND of novel BLI for pairing with cefixime
Luigi Xerri · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Discovery of inhibitors of Zika virus
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health